Cardiac dysfunction is a common and important manifestation of diabetes mellitus. It is well recognized that cardiomyopathy occurs frequently in diabetic patients in the absence of known cardiac risk factors. Although little is known about the pathogenesis of diabetic cardiomyopathy, evidence is emerging that cardiac dysfunction in the diabetic heart is related to perturbations in myocardial metabolism caused primarily or secondarily by insulin deficiency or resistance. In uncontrolled diabetes, the myocardial extraction and utilization of fat is markedly increased such that the diabetic heart relies almost exclusively on mitochondrial fatty acid oxidation (FAO) for its ATP requirements. Recent studies have defined an important role for the lipid-activated transcription factor, the peroxisome proliferator-activated receptor alpha (PPARalpha), in the control of cardiac fatty acid utilization pathways. Our preliminary data indicates that the activation of cardiac fatty acid utilization in the diabetic heart is mediated by the PPARalpha gene regulatory pathway. Our preliminary data indicates that the activation of cardiac fatty acid utilization in the diabetic heart is mediated by the PPARalpha gene regulatory pathway. This proposal is designed to test the hypothesis that lipid metabolic alterations secondary to increased activity of PPARalpha lead to pathologic remodeling in the diabetic heart. Such pathologic remodeling could occur due top increased oxygen consumption or through toxic lipid intermediates generated by peroxisomal or mitochondrial pathways. This hypothesis will be tested by the phenotypic characterization of mice with cardiac-specific over- expression of PPARalpha (MHC-PPAR mice). First, the lipid metabolic and cardiac functional phenotypic of multiple independent lines of MHC-PPARalpha transgenic mice will be evaluated and compared with that of mice rendered diabetic via administration of streptozotocin. Second, the role of PPARalpha in the expression and severity of diabetic cardiomyopathy will be determined by altering its activity via genetically engineered loss-of-function (PPARalpha null mice) and gain- of-function (MHC-PPAR mice) in the context of three different murine models of diabetes. Lastly, the role of altered peroxisomal function in MHC-PPAR mice compared to diabetic mice. The long term goal of this project is to delineate the precise molecular and metabolic bases for diabetic cardiomyopathy including identification of specific lipid mediators of cardiac dysfunction. This work should lead to the development of novel therapeutic strategies aimed at modulating cardiac lipid metabolism to reduced the cardiovascular morbidity and morality in diabetic patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL057278-06A1
Application #
6591379
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2002-04-01
Project End
2007-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
6
Fiscal Year
2002
Total Cost
$341,548
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Beirowski, Bogdan; Babetto, Elisabetta; Golden, Judith P et al. (2014) Metabolic regulator LKB1 is crucial for Schwann cell-mediated axon maintenance. Nat Neurosci 17:1351-61
Lei, Xiaoyong; Bone, Robert N; Ali, Tomader et al. (2014) Evidence of contribution of iPLA2?-mediated events during islet ?-cell apoptosis due to proinflammatory cytokines suggests a role for iPLA2? in T1D development. Endocrinology 155:3352-64
Jenkins, Christopher M; Yang, Jingyue; Gross, Richard W (2013) Mechanism-based inhibition of iPLA2? demonstrates a highly reactive cysteine residue (C651) that interacts with the active site: mass spectrometric elucidation of the mechanisms underlying inhibition. Biochemistry 52:4250-63
Pacheco, Sophia A; Hsu, Fong-Fu; Powers, Katelyn M et al. (2013) MmpL11 protein transports mycolic acid-containing lipids to the mycobacterial cell wall and contributes to biofilm formation in Mycobacterium smegmatis. J Biol Chem 288:24213-22
Lei, Xiaoyong; Bone, Robert N; Ali, Tomader et al. (2013) Genetic modulation of islet ?-cell iPLA?? expression provides evidence for its impact on ?-cell apoptosis and autophagy. Islets 5:29-44
Kuda, Ondrej; Pietka, Terri A; Demianova, Zuzana et al. (2013) Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages. J Biol Chem 288:15547-55
Yang, Kui; Dilthey, Beverly Gibson; Gross, Richard W (2013) Identification and quantitation of fatty acid double bond positional isomers: a shotgun lipidomics approach using charge-switch derivatization. Anal Chem 85:9742-50
Viader, Andreu; Sasaki, Yo; Kim, Sungsu et al. (2013) Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron 77:886-98
Kiebish, Michael A; Yang, Kui; Liu, Xinping et al. (2013) Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome. J Lipid Res 54:1312-25
Kiebish, Michael A; Yang, Kui; Sims, Harold F et al. (2012) Myocardial regulation of lipidomic flux by cardiolipin synthase: setting the beat for bioenergetic efficiency. J Biol Chem 287:25086-97

Showing the most recent 10 out of 180 publications